<DOC>
	<DOCNO>NCT01713179</DOCNO>
	<brief_summary>Ambroxol metabolite bromhexine possess mucokinetic secretolytic property also find mucolytic agents.1 Ambroxol use decade treatment respiratory disorder associate excessive mucus , include chronic inflammatory pulmonary condition , bronchitis , pneumonia.2,3 The drug change biophysical property secretion degrade mucin polymer , deoxyribonucleic acid , fibrin airway secretion , generally decrease viscosity.4 In addition , ambroxol increase cyclic nucleotide ( cAMP cGMP ) ,5 theoretically increase tear secretion.6 Many systemic medication , antihistamine , antidepressant , diuretic , acne drug , certain blood pressure medicine cause exacerbate dry eye.7,8 On hand , several topical medication , include mucolytics ambroxol bromhexine , may use treat tear-deficient dry eye promote lacrimal gland function.9 However , effect mucoactive agent tear film investigate systemically , mucoactive agent may disturb effect tear film modify mucin.10,11 The tear film compose 3 unique layer , include outermost lipid layer , middle aqueous layer , innermost mucus layer ; structure enable perform many functions.12 The lipid layer act barrier prevent tear film evaporation , aqueous layer supply oxygen important nutrient cornea.13 The mucin layer , secrete mostly conjunctival goblet cell , coat corneal surface render hydrophilic , anchor tear film corneal surface.14 Deficiencies amount tear production alteration tear composition lead ocular surface disease.15 Although many study focus aqueous-deficient dry eye syndrome,16-18 effect mucin layer defect tear film thoroughly study . Furthermore , report determine effect oral mucolytic agent tear film ocular surface , although study report filamentary keratopathy treat debridement filament application topical mucolytic agent acetylcysteine eyedrop . In present study , investigated effect oral ambroxol tear film ocular surface . Reference 1 . Malerba M , Ragnoli B. Ambroxol 21st century : pharmacological clinical update . Expert Opin Drug Metab Toxicol 2008 ; 4:1119-1129 . 2 . Rubin BK . Mucolytics , expectorant , mucokinetic medication . Respir Care 2007 ; 52:859-865 . 3 . Rogers DF . Mucoactive agent airway mucus hypersecretory disease . Respir Care 2007 ; 52:1176-1193 . 4 . Gupta PR . Ambroxol - Resurgence old molecule anti-inflammatory agent chronic obstructive airway disease . Lung India 2010 ; 27:46-48 . 5 . Anfossi G , Russo I , Massucco P , et al . Adenosine increase human platelet level cGMP nitric oxide : possible role antiaggregating effect . Thromb Res 2002 ; 105:71-78 . 6 . Gilbard JP , Rossi SR , Heyda KG , et al . Stimulation tear secretion topical agent increase cyclic nucleotide level . Invest Ophthalmol Vis Sci 1990 ; 31:1381-1388 . 7 . Gayton JL . Etiology , prevalence , treatment dry eye disease . Clin Ophthalmol 2009 ; 3:405-412 . 8 . Terry MA . Dry eye elderly . Drugs Aging 2001 ; 18:101-107 . 9 . Calonge M. The treatment dry eye . Surv Ophthalmol 2001 ; 45:227-239 . 10 . Yamada T , Takemura Y , Niisato N , et al . Action N-acylated ambroxol derivative secretion chloride ion human airway epithelium . Biochem Biophys Res Commun 2009 ; 380:586-590 . 11 . Hasegawa I , Niisato N , Iwasaki Y , et al . Ambroxol-induced modification ion transport human airway Calu-3 epithelium . Biochem Biophys Res Commun 2006 ; 343:475-482 . 12 . Antti H , Tuulikki S , Matej O . Human tear fluid lipidome : composition function . PLoS One 2011 ; 6 : e19553 . 13 . Ohashi Y , Dogru M , Tsubota K. Laboratory finding tear fluid analysis . Clin Chim Acta 2006 ; 396:17-28 . 14 . Davidson HJ , Kuonen VJ . The tear film ocular mucin . Vet Ophthalmol 2004 ; 7:71-77 . 15 . Bhavsar AS , Bhavsar SG , Jain SM . A review recent advance dry eye : pathogenesis management . Oman J Ophthalmol 2011 ; 4:50-56 . 16 . Patel S , Farrell J , Blades KJ , et al . The value phenol red impregnated thread differentiate aqueous non-aqueous deficient dry eye . Ophthalmic Physiol Opt 1998 ; 18:471-476 . 17 . Lin H , Li W , Dong N , et al . Changes corneal epithelial layer inflammatory cell aqueous tear-deficient dry eye . Invest Ophthalmol Vis Sci 2010 ; 51:122-128 . 18 . Yokoi N , Yamada H , Mizukusa Y , et al . Rheology tear film lipid layer spread normal aqueous tear-deficient dry eye . Invest Ophthalmol Vis Sci 2008 ; 49:5319-5324 .</brief_summary>
	<brief_title>Effects Oral Mucolytics Tear Film Ocular Surface</brief_title>
	<detailed_description />
	<mesh_term>Ambroxol</mesh_term>
	<criteria>Twenty healthy male volunteer age 25 29 year Subjects dry eye symptom within previous 6 month exclude study . Subjects systemic disease systemic lupus , rheumatoid arthritis , Sj√∂gren 's syndrome history ocular disease . Subjects disorder lid margin , nasolacrimal duct , cornea .</criteria>
	<gender>Male</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>